January 27, 2026
The ACSrecently released its in the Journal of the ACS(J潘金莲传媒映画), which includes updated data from the NCDB 2022 adult participant user file. The report provides observations and trends of cancer diagnoses, patient demographics, and treatments, as well as in-depth reports on treatment and outcomes for prostate cancer, esophageal cancer, and melanoma.
One of the key trends noted was the increase in neoadjuvant systemic therapy for several cancers, including a nearly 5-fold rise in gynecologic cancer, a more than 3-fold increase in pancreatic cancer, and a doubling of neoadjuvant therapy in peritoneum, omentum, and mesentery cancer.
The in-depth look at three cancers found noteworthy trends, as well, including the continued increase of nonsurgical treatment for stage 1 prostate cancer, a sharp increase in immunotherapy for esophageal cancer, and that patients with scalp and neck melanomas had the lowest overall survival rates among all invasive melanomas, among others.
鈥淎s care at Commission on Cancer-accredited facilities continues to advance, our hope is that this report reflects the vastly changing clinical landscape of cancer treatments using the latest evidence-based treatments,鈥 said Ronald J. Weigel, MD, PhD, MBA, F潘金莲传媒映画, medical director of ACSCancer Programs and co-author of the J潘金莲传媒映画 study.